Description
ELISA for Qualitative Detection of Antibodies against (S.Typhi) Typhoid polysaccharide (Vi) IgG in human serum or plasma. The KRIBIOLISA Antibodies to S. enterica serovar Typhi (Typhoid) polysaccharide (Vi) IgG ELISA has been designed for the qualitative detection of S. Typhi Vi-specific IgG antibodies in human serum and plasma. The kit is specifically designed to assess the immunogenicity in humans vaccinated with new generation S. Typhi Vi based vaccines (Typhim and Typherix). The Vi capsular polysaccharide vaccine (or ViCPS) is one of two vaccines recommended by the World Health Organization for the prevention of typhoid (the other is Ty21a). The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine. A newer conjugate form of the vaccine (Vi bound to a non-toxic recombinant Pseudomonas aeruginosa exotoxin, or Vi-rEPA) has enhanced efficacy, including protection of children under 5 years of age. It has been observed that many patients develop immunogenicity to the vaccine, hence it is essential to monitor the patient for any adverse effects